首页 > 最新文献

Cardiovascular diagnosis and therapy最新文献

英文 中文
Early diagnostic and prognostic value of myocardial strain derived from cardiovascular magnetic resonance in patients with cardiac amyloidosis 心血管磁共振得出的心肌应变对心脏淀粉样变性患者的早期诊断和预后价值
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-205
Weijie Hou, Zhi Wang, Jingzhou Huang, Fangfang Fan, Fan Yang, Lin Qiu, Kai Zhao, Jianxing Qiu, Ying Yang, Wei Ma, Yanjun Gong, Tao Hong
{"title":"Early diagnostic and prognostic value of myocardial strain derived from cardiovascular magnetic resonance in patients with cardiac amyloidosis","authors":"Weijie Hou, Zhi Wang, Jingzhou Huang, Fangfang Fan, Fan Yang, Lin Qiu, Kai Zhao, Jianxing Qiu, Ying Yang, Wei Ma, Yanjun Gong, Tao Hong","doi":"10.21037/cdt-23-205","DOIUrl":"https://doi.org/10.21037/cdt-23-205","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"2 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139024213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of left ventricular ejection fraction improvement in patients with ischemic cardiomyopathy after coronary artery bypass grafting based on cardiac magnetic resonance 基于心脏磁共振预测冠状动脉旁路移植术后缺血性心肌病患者左心室射血分数的改善情况
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-220
Kui Zhang, Wei Fu, Qinyi Dai, Tao-shuai Liu, Jubing Zheng, Yue Song, Hongkai Zhang, Jumatay Biekan, Ran Dong
{"title":"Prediction of left ventricular ejection fraction improvement in patients with ischemic cardiomyopathy after coronary artery bypass grafting based on cardiac magnetic resonance","authors":"Kui Zhang, Wei Fu, Qinyi Dai, Tao-shuai Liu, Jubing Zheng, Yue Song, Hongkai Zhang, Jumatay Biekan, Ran Dong","doi":"10.21037/cdt-23-220","DOIUrl":"https://doi.org/10.21037/cdt-23-220","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"77 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138988178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fractal analysis in cardiovascular magnetic resonance: prognostic value of biventricular trabecular complexity in hypertrophic cardiomyopathy 心血管磁共振中的分形分析:肥厚型心肌病双心室小梁复杂性的预后价值
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-162
Wen-Yi Jiang, Binghua Chen, Chen Zhang, R. Shi, Rui Wu, D. An, Xiao-Hai Ma, L. Wesemann, Jiani Hu, Yan Zhou, Jian-rong Xu, Lei Zhao, Lian-Ming Wu
{"title":"Fractal analysis in cardiovascular magnetic resonance: prognostic value of biventricular trabecular complexity in hypertrophic cardiomyopathy","authors":"Wen-Yi Jiang, Binghua Chen, Chen Zhang, R. Shi, Rui Wu, D. An, Xiao-Hai Ma, L. Wesemann, Jiani Hu, Yan Zhou, Jian-rong Xu, Lei Zhao, Lian-Ming Wu","doi":"10.21037/cdt-23-162","DOIUrl":"https://doi.org/10.21037/cdt-23-162","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"6 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138992719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Takotsubo syndrome: unravelling the enigma of the broken heart syndrome?—a narrative review 塔克次博综合征:揭开心脏破裂综合征之谜?
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-283
J. Salamanca, Fernando Alfonso
{"title":"Takotsubo syndrome: unravelling the enigma of the broken heart syndrome?—a narrative review","authors":"J. Salamanca, Fernando Alfonso","doi":"10.21037/cdt-23-283","DOIUrl":"https://doi.org/10.21037/cdt-23-283","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"238 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139018517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstructive sleep apnea remains a risk factor for major adverse cardiovascular and cerebrovascular events even in hypertensive patients under treatment: the Urumqi Research on Sleep Apnea and Hypertension (UROSAH) data 即使在接受治疗的高血压患者中,阻塞性睡眠呼吸暂停仍是导致重大不良心脑血管事件的风险因素:乌鲁木齐睡眠呼吸暂停与高血压研究(UROSAH)数据
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-284
X. Yao, Nanfang Li, M. Heizhati, Ying-chun Wang, Yue Ma, Run Wang, De-lian Zhang, Q. Luo, Junli Hu, Meng-hui Wang, Qing Zhu
{"title":"Obstructive sleep apnea remains a risk factor for major adverse cardiovascular and cerebrovascular events even in hypertensive patients under treatment: the Urumqi Research on Sleep Apnea and Hypertension (UROSAH) data","authors":"X. Yao, Nanfang Li, M. Heizhati, Ying-chun Wang, Yue Ma, Run Wang, De-lian Zhang, Q. Luo, Junli Hu, Meng-hui Wang, Qing Zhu","doi":"10.21037/cdt-23-284","DOIUrl":"https://doi.org/10.21037/cdt-23-284","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"45 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139023058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum levels of carbohydrate antigen 125 in patients with heart failure and obstructive sleep apnea syndrome: a retrospective analysis 心力衰竭和阻塞性睡眠呼吸暂停综合征患者血清中碳水化合物抗原 125 的水平:回顾性分析
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-323
Tiantian Ge, Songsong Song, Shengnan Li, Xiaojin Yu, Liangfa Shao, Jiayi Tong
{"title":"Serum levels of carbohydrate antigen 125 in patients with heart failure and obstructive sleep apnea syndrome: a retrospective analysis","authors":"Tiantian Ge, Songsong Song, Shengnan Li, Xiaojin Yu, Liangfa Shao, Jiayi Tong","doi":"10.21037/cdt-23-323","DOIUrl":"https://doi.org/10.21037/cdt-23-323","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"79 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139024803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IgG4-related disease involving coronary and pulmonary arteries: a case report and literature review 涉及冠状动脉和肺动脉的 IgG4 相关疾病:病例报告和文献综述
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-215
Jin Cao, Zhaowen Yang
{"title":"IgG4-related disease involving coronary and pulmonary arteries: a case report and literature review","authors":"Jin Cao, Zhaowen Yang","doi":"10.21037/cdt-23-215","DOIUrl":"https://doi.org/10.21037/cdt-23-215","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"70 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139016499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pacemaker leads as a potential source of problems in patients who might need a central venous access port 起搏器导线是可能需要中心静脉通路端口的患者的潜在问题来源
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-104
M. Czajkowski, A. Polewczyk, W. Jacheć, D. Nowosielecka, Łukasz Tułecki, P. Stefańczyk, Andrzej Kutarski
{"title":"Pacemaker leads as a potential source of problems in patients who might need a central venous access port","authors":"M. Czajkowski, A. Polewczyk, W. Jacheć, D. Nowosielecka, Łukasz Tułecki, P. Stefańczyk, Andrzej Kutarski","doi":"10.21037/cdt-23-104","DOIUrl":"https://doi.org/10.21037/cdt-23-104","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"286 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bypass failure of internal mammary artery caused by subclavian artery stenosis: its clinical characteristics and cardiovascular outcomes in patients receiving coronary artery bypass graft surgery 锁骨下动脉狭窄导致的乳内动脉旁路失败:接受冠状动脉旁路移植手术患者的临床特征和心血管预后
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-01 DOI: 10.21037/cdt-23-211
Nobunari Tomura, Y. Kataoka, Kensuke Morris, Eri Kiyoshige, Kunihiro Nishimura, N. Yagi, Kota Murai, T. Iwai, K. Sawada, H. Matama, Satoshi Honda, M. Fujino, Kensuke Takagi, S. Yoneda, F. Otsuka, Yoshio Tahara, Y. Asaumi, T. Satow, Hiroharu Kataoka, Satsuki Fukushima, Tomoyuki Fujita, T. Noguchi
{"title":"Bypass failure of internal mammary artery caused by subclavian artery stenosis: its clinical characteristics and cardiovascular outcomes in patients receiving coronary artery bypass graft surgery","authors":"Nobunari Tomura, Y. Kataoka, Kensuke Morris, Eri Kiyoshige, Kunihiro Nishimura, N. Yagi, Kota Murai, T. Iwai, K. Sawada, H. Matama, Satoshi Honda, M. Fujino, Kensuke Takagi, S. Yoneda, F. Otsuka, Yoshio Tahara, Y. Asaumi, T. Satow, Hiroharu Kataoka, Satsuki Fukushima, Tomoyuki Fujita, T. Noguchi","doi":"10.21037/cdt-23-211","DOIUrl":"https://doi.org/10.21037/cdt-23-211","url":null,"abstract":"","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"59 17","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138985961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Very long-term efficacy and safety of paclitaxel-eluting balloon after a bare-metal stent for the treatment of ST-elevation myocardial infarction: 8-year results of a randomized clinical trial (PEBSI study). 裸金属支架后紫杉醇洗脱球囊治疗ST段抬高型心肌梗死的长期疗效和安全性:一项随机临床试验的8年结果(PEBSI研究)。
IF 2.4 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-10-31 Epub Date: 2023-10-17 DOI: 10.21037/cdt-22-623
Arturo García-Touchard, Manel Sabaté, Nieves Gonzalo, Vicente Peral, Beatriz Vaquerizo, Rafael Ruiz-Salmerón, Bruno García Del Blanco, Jesús Jiménez-Mazuecos, Eduardo Molina, Pedro Martínez-Romero, José María Hernandez-García, Valeriano Ruiz-Quevedo, Cristóbal Urbano, Javier Fernández-Portales, José Ramón Rumoroso, Juan Casanova-Sandoval, Eduardo Pinar, Javier Lopez-Pais, Juan Francisco Oteo, Fernando Alfonso

Background: Drug-eluting stents (DES) are considered the therapy of choice in ST-segment elevation myocardial infarction (STEMI); however, a low persistent rate of revascularizations and stent thrombosis exist over the time. We have previously shown that a paclitaxel (PTX)-drug-coated balloon (DCB) after a bare-metal stent (BMS) implantation (DCB-combined strategy) yields superior angiographic and clinical results compared to BMS in the short term. However, the long-term safety and efficacy of this approach remain uncertain.

Methods: An 8-year clinical follow-up was conducted on patients enrolled in the randomized PEBSI-1 trial (NCT01839890). The original trial included patients who suffered a STEMI, patients were randomly assigned to receive a DCB-combined strategy or BMS only and the primary endpoint was in-stent late luminal loss (LLL) at 9-month follow-up. After the completion of this study, death, myocardial re-infarction, ischemia-driven repeated revascularizations included target lesion revascularization (TLR) and target vessel revascularization (TVR), and stent thrombosis, were assessed by yearly contact by a clinical visit, telephone or by electronic records. These outcomes were adhered to ARC-2 criteria.

Results: The rate of incomplete follow-up was very low, with only 3 out of 111 patients (2.7%) in the DCB-combined strategy group and 1 out of 112 patients (0.9%) in the BMS group. At 8 years there were a lower rate of TVR [3.7% vs. 14.3%; hazard ratio (HR): 0.243; 95% confidence interval (CI): 0.081-0.727; P=0.006], and a trend towards lower TLR (2.8% vs. 8.9%; HR: 0.300; 95% CI: 0.083-1.090; P=0.052) in the DCB-combined strategy group. No statistical difference between the DCB-combined strategy and BMS groups were found for all causes of death, deaths from cardiovascular disease, reinfarctions or stent thrombosis. Notably in the DCB-combined strategy group, no episode of stent thrombosis occurred after the first year. Similarly, there were no cardiovascular deaths, TVR and TLR in the DCB-combined strategy group after 5 years. In contrast, during the period from year 5 to 8, the BMS group experienced an additional cardiovascular death, as well as one case of TVR, one case of TLR, and one case of stent thrombosis.

Conclusions: In STEMI patients, the DCB-combined strategy maintains its safety and clinical efficacy over time. Our rates of TVR, TLR, and very late stent thrombosis (VLST) at very long-term are the lowest ever found in a STEMI trial. Further studies are warranted to assess the potential superiority of this novel strategy as compared with new-generation DES to prevent very late events in these patients.

Trial registration: ClinicalTrials.gov; identifier: NCT01839890.

背景:药物洗脱支架(DES)被认为是ST段抬高型心肌梗死(STEMI)的首选治疗方法;然而,随着时间的推移,血运重建和支架血栓形成的持续率较低。我们之前已经表明,与BMS相比,裸金属支架(BMS)植入后的紫杉醇(PTX)-药物涂层球囊(DCB)(DCB联合策略)在短期内产生了更好的血管造影和临床结果。然而,这种方法的长期安全性和有效性仍不确定。方法:对纳入随机PEBSI-1试验(NCT01839890)的患者进行8年的临床随访。最初的试验包括STEMI患者,患者被随机分配接受DCB联合策略或仅接受BMS,主要终点是9个月随访时支架内晚期管腔损失(LLL)。本研究完成后,每年通过临床访视、电话或电子记录对死亡、心肌再梗死、缺血驱动的重复血运重建(包括靶病变血运重建术(TLR)和靶血管血运重建法(TVR))以及支架血栓形成进行评估。这些结果符合ARC-2标准。结果:不完全随访率非常低,DCB联合策略组111例患者中只有3例(2.7%),BMS组112例患者中有1例(0.9%)。在8年时,DCB联合策略组的TVR较低[3.7%对14.3%;危险比(HR):0.243;95%置信区间(CI):0.081-0.727;P=0.006],TLR有降低的趋势(2.8%对8.9%;HR:0.300;95%CI:0.83-1.090;P=0.052)。DCB联合策略和BMS组在所有死亡原因、心血管疾病死亡、再梗死或支架血栓形成方面没有发现统计学差异。值得注意的是,在DCB联合策略组中,第一年后没有发生支架血栓形成。同样,DCB联合策略组5年后没有心血管死亡、TVR和TLR。相反,在第5年至第8年期间,BMS组经历了一例额外的心血管死亡,以及一例TVR、一例TLR和一例支架血栓形成。结论:在STEMI患者中,DCB联合策略随着时间的推移保持其安全性和临床疗效。我们的长期TVR、TLR和晚期支架血栓形成(VLST)的发生率是STEMI试验中发现的最低的。需要进一步的研究来评估与新一代DES相比,这种新策略在预防这些患者的晚期事件方面的潜在优势。试验注册:ClinicalTrials.gov;标识符:NCT01839890。
{"title":"Very long-term efficacy and safety of paclitaxel-eluting balloon after a bare-metal stent for the treatment of ST-elevation myocardial infarction: 8-year results of a randomized clinical trial (PEBSI study).","authors":"Arturo García-Touchard, Manel Sabaté, Nieves Gonzalo, Vicente Peral, Beatriz Vaquerizo, Rafael Ruiz-Salmerón, Bruno García Del Blanco, Jesús Jiménez-Mazuecos, Eduardo Molina, Pedro Martínez-Romero, José María Hernandez-García, Valeriano Ruiz-Quevedo, Cristóbal Urbano, Javier Fernández-Portales, José Ramón Rumoroso, Juan Casanova-Sandoval, Eduardo Pinar, Javier Lopez-Pais, Juan Francisco Oteo, Fernando Alfonso","doi":"10.21037/cdt-22-623","DOIUrl":"10.21037/cdt-22-623","url":null,"abstract":"<p><strong>Background: </strong>Drug-eluting stents (DES) are considered the therapy of choice in ST-segment elevation myocardial infarction (STEMI); however, a low persistent rate of revascularizations and stent thrombosis exist over the time. We have previously shown that a paclitaxel (PTX)-drug-coated balloon (DCB) after a bare-metal stent (BMS) implantation (DCB-combined strategy) yields superior angiographic and clinical results compared to BMS in the short term. However, the long-term safety and efficacy of this approach remain uncertain.</p><p><strong>Methods: </strong>An 8-year clinical follow-up was conducted on patients enrolled in the randomized PEBSI-1 trial (NCT01839890). The original trial included patients who suffered a STEMI, patients were randomly assigned to receive a DCB-combined strategy or BMS only and the primary endpoint was in-stent late luminal loss (LLL) at 9-month follow-up. After the completion of this study, death, myocardial re-infarction, ischemia-driven repeated revascularizations included target lesion revascularization (TLR) and target vessel revascularization (TVR), and stent thrombosis, were assessed by yearly contact by a clinical visit, telephone or by electronic records. These outcomes were adhered to ARC-2 criteria.</p><p><strong>Results: </strong>The rate of incomplete follow-up was very low, with only 3 out of 111 patients (2.7%) in the DCB-combined strategy group and 1 out of 112 patients (0.9%) in the BMS group. At 8 years there were a lower rate of TVR [3.7% <i>vs.</i> 14.3%; hazard ratio (HR): 0.243; 95% confidence interval (CI): 0.081-0.727; P=0.006], and a trend towards lower TLR (2.8% <i>vs.</i> 8.9%; HR: 0.300; 95% CI: 0.083-1.090; P=0.052) in the DCB-combined strategy group. No statistical difference between the DCB-combined strategy and BMS groups were found for all causes of death, deaths from cardiovascular disease, reinfarctions or stent thrombosis. Notably in the DCB-combined strategy group, no episode of stent thrombosis occurred after the first year. Similarly, there were no cardiovascular deaths, TVR and TLR in the DCB-combined strategy group after 5 years. In contrast, during the period from year 5 to 8, the BMS group experienced an additional cardiovascular death, as well as one case of TVR, one case of TLR, and one case of stent thrombosis.</p><p><strong>Conclusions: </strong>In STEMI patients, the DCB-combined strategy maintains its safety and clinical efficacy over time. Our rates of TVR, TLR, and very late stent thrombosis (VLST) at very long-term are the lowest ever found in a STEMI trial. Further studies are warranted to assess the potential superiority of this novel strategy as compared with new-generation DES to prevent very late events in these patients.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov; identifier: NCT01839890.</p>","PeriodicalId":9592,"journal":{"name":"Cardiovascular diagnosis and therapy","volume":"13 5","pages":"792-804"},"PeriodicalIF":2.4,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71520645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular diagnosis and therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1